Patients with gastric intestinal metaplasia after endoscopic therapy for early-stage gastric cancer intestinal metaplasia
Conditions
Interventions
After the study registry, intestinal metaplasia score of gastric corpus upper gastrointestinal endoscopy and gastric biopsy (updated Sydney system) is evaluated, and only cases with 2 or more score co
D001599
berberine
Sponsors
Sue Soichiro
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: (1)Person who have endoscopic therapy history for early-gastric cancer and whose early-gastric cancer was pathologically curative resected. Gastric cancer histological type is note limited. (2)Person whose background gastric mucosa at the point of endoscopic therapy for early-gastric cancer was diagnosed as histological intestinal metaplasia (3)Person who is 20 years or older (4)Both sexes (5)Person who can declare agreement for registering by understanding the study and signing the document after hearing the explanation
Exclusion criteria
Exclusion criteria: (1)Person who take berberine as medication within a year (2)Person who take berberine as supplement within a year (3)Hemorrhagic colitis patient (4)Bacterial enteritis patient (5)Patient who successfully eradicated Helicobacter pylori within a year (6)Patient regularly taking COX2 inhibitor (7)Patient regularly taking NSAIDs (8)Patient regularly taking anticoagulants (warfarin, edoxaban, dabigatran, rivaroxaban, apixaban) (9)Patient regularly taking antiplatelet drug (aspirin, ticlopidine, clopidogrel, cilostazol, Ethyl icosapentate, clopidogrel) (10)Pregnant (11)Patients who are disqualified for the study by physicians
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Improvement rate of histological intestinal metaplasia in gastric corpus Definition: In this study, patients with two or more score of intestinal metaplasia score (updated sydney system) in gastric corpus are intervened. After the intervention with berberine group or control group, patients with one or less the score defined as improved. Primary outcome is improvement rate. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1) Change between before and after intervention: histological intestinal metaplasia score of gastric corpus (updated Sydney system) 2) Change between before and after intervention: histological intestinal metaplasia score of gastric antrum (updated Sydney system) 3) Change between before and after intervention: histological intestinal metaplasia score of gastric angle (updated Sydney system) 4) Change between before and after intervention: histological chronic inflammation score of gastric corpus (updated Sydney system) 5) Change between before and after intervention: histological chronic inflammation score of gastric antrum (updated Sydney system) 6) Change between before and after intervention: histological chronic inflammation score of gastric angle (updated Sydney system) 7) Change between before and after intervention: histological acute inflammation score of gastric corpus (updated Sydney system) 8) Change between before and after intervention: histological acute inflammation score of gastric antrum (updated Sydney system) 9) Change between before and after intervention: histological acute inflammation score of gastric angle (updated Sydney system) 10) Change between before and after intervention: histological atrophy score of gastric corpus (updated Sydney system) 11) Change between before and after intervention: histological atrophy score of gastric antrum (updated Sydney system) 12) Change between before and after intervention: histological atrophy score of gastric angle (updated Sydney system) 13) Change between before and after intervention: Total endoscopic gastric cancer risk score (Kyoto classification of gastritis): total of atrophy, intestinal metaplasia, diffuse redness, enlarged fold, and nodular. 14) Change between before and after intervention: endoscopic atrophy score (Kyoto classification of gastritis) 15) Change between before and after intervention: endoscopic intestinal metaplasia score (Kyoto classification of gastritis) 16) Change betw | — |
Contacts
Public ContactSoichiro Sue
Yokohama City University Hospital
Outcome results
None listed